Back to Search Start Over

MicroRNA-664 suppresses the growth of cervical cancer cells via targeting c-Kit

Authors :
Qianwen Zhang
Keyu Wang
Rongying Ou
Fan Lin
Xiangyun Li
Mingfen Lv
Yunsheng Xu
Source :
Drug Design, Development and Therapy. 13:2371-2379
Publication Year :
2019
Publisher :
Informa UK Limited, 2019.

Abstract

Background Cervical cancer is the second most common malignant cancer in women worldwide. Evidence indicated that miR-664 was significantly downregulated in cervical cancer. However, the mechanisms by which miR-664 regulates the tumorigenesis of cervical cancer remain unclear. Thus, this study aimed to investigate the role of miR-664 in cervical cancer. Methods Quantitative reverse transcription polymerase chain reaction was used to detect the level of miR-664 in tumor tissues and cell line. The dual luciferase reporter system assay and Western blotting were used to explore the interaction of miR-664 and c-Kit in cervical cancer. Results The expression of miR-664 in patients with cervical cancer was dramatically decreased compared with that in adjacent tissues. MiR-664 mimics significantly inhibited proliferation in SiHa cells via inducing apoptosis. In addition, miR-664 mimics induced apoptosis in SiHa cells via increasing the expressions of Bax and active caspase 3 and decreasing the level of Bcl-2. Moreover, dual-luciferase assay showed that c-Kit was the directly binding target of miR-664 in SiHa cells; overexpression of miR-664 downregulated the expression of c-Kit. Meanwhile, upregulation of miR-664 significantly decreased the levels of c-Myc and Cyclin D in cells. Furthermore, miR-664 markedly inhibited tumor growth of cervical cancer in xenograft. Conclusion Our data indicated that miR-664 exerted antitumor effects on SiHa cells by directly targeting c-Kit in vitro and in vivo. Therefore, miR-664 might be a potential therapeutic target for the treatment of patients with cervical cancer.

Details

ISSN :
11778881
Volume :
13
Database :
OpenAIRE
Journal :
Drug Design, Development and Therapy
Accession number :
edsair.doi...........b5951d7ce7f137af837b2d54fa1b9784